406 related articles for article (PubMed ID: 24237224)
1. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.
Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Carnevale-Schianca F; Aglietta M; Sangiolo D
Anticancer Agents Med Chem; 2014 Feb; 14(2):211-22. PubMed ID: 24237224
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy against sarcomas.
Mesiano G; Leuci V; Giraudo L; Gammaitoni L; Carnevale Schianca F; Cangemi M; Rotolo R; Capellero S; Pignochino Y; Grignani G; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2015 Apr; 15(4):517-28. PubMed ID: 25516119
[TBL] [Abstract][Full Text] [Related]
3. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition.
Elia AR; Circosta P; Sangiolo D; Bonini C; Gammaitoni L; Mastaglio S; Genovese P; Geuna M; Avolio F; Inghirami G; Tarella C; Cignetti A
Hum Gene Ther; 2015 Apr; 26(4):220-31. PubMed ID: 25758764
[TBL] [Abstract][Full Text] [Related]
5. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.
Mesiano G; Todorovic M; Gammaitoni L; Leuci V; Giraudo Diego L; Carnevale-Schianca F; Fagioli F; Piacibello W; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2012 Jun; 12(6):673-84. PubMed ID: 22500889
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives.
Giraudo L; Gammaitoni L; Cangemi M; Rotolo R; Aglietta M; Sangiolo D
Immunotherapy; 2015; 7(9):999-1010. PubMed ID: 26310715
[TBL] [Abstract][Full Text] [Related]
7. CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy.
Rotolo R; Leuci V; Donini C; Cykowska A; Gammaitoni L; Medico G; Valabrega G; Aglietta M; Sangiolo D
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212634
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective.
Gammaitoni L; Leuci V; Mesiano G; Giraudo L; Todorovic M; Carnevale-Schianca F; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2014 Sep; 14(9):1259-70. PubMed ID: 24835841
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
10. NK cell-based cancer immunotherapy: from basic biology to clinical application.
Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
[TBL] [Abstract][Full Text] [Related]
11. Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells.
Cappuzzello E; Sommaggio R; Zanovello P; Rosato A
Cytokine Growth Factor Rev; 2017 Aug; 36():99-105. PubMed ID: 28629761
[TBL] [Abstract][Full Text] [Related]
12. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
[TBL] [Abstract][Full Text] [Related]
13. Cancer Immunotherapy with Cytokine-Induced Killer Cells.
Mata-Molanes JJ; Sureda González M; Valenzuela Jiménez B; Martínez Navarro EM; Brugarolas Masllorens A
Target Oncol; 2017 Jun; 12(3):289-299. PubMed ID: 28474278
[TBL] [Abstract][Full Text] [Related]
14. Immunologic mechanisms of antitumor activity.
Foss FM
Semin Oncol; 2002 Jun; 29(3 Suppl 7):5-11. PubMed ID: 12068382
[TBL] [Abstract][Full Text] [Related]
15. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.
Sangiolo D; Mesiano G; Carnevale-Schianca F; Piacibello W; Aglietta M; Cignetti A
Expert Opin Biol Ther; 2009 Jul; 9(7):831-40. PubMed ID: 19463075
[TBL] [Abstract][Full Text] [Related]
16. Tumour MHC class I downregulation and immunotherapy (Review).
Bubeník J
Oncol Rep; 2003; 10(6):2005-8. PubMed ID: 14534734
[TBL] [Abstract][Full Text] [Related]
17. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
Guo H; Qian X
Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers.
Todorovic M; Mesiano G; Gammaitoni L; Leuci V; Giraudo Diego L; Cammarata C; Jordaney N; Carnevale-Schianca F; Gallo S; Fagioli F; Piacibello W; Elia AR; Pignochino Y; Dell'aglio C; Grignani G; Cignetti A; Aglietta M; Sangiolo D
J Immunother; 2012 Sep; 35(7):579-86. PubMed ID: 22892454
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway.
Iudicone P; Fioravanti D; Cicchetti E; Zizzari IG; Pandolfi A; Scocchera R; Fazzina R; Pierelli L
Hum Immunol; 2016 Dec; 77(12):1239-1247. PubMed ID: 27615504
[TBL] [Abstract][Full Text] [Related]
20. Can the dual-functional capability of CIK cells be used to improve antitumor effects?
Wang X; Yu W; Li H; Yu J; Zhang X; Ren X; Cao S
Cell Immunol; 2014 Jan; 287(1):18-22. PubMed ID: 24355711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]